These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516 [TBL] [Abstract][Full Text] [Related]
4. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. Tornoci L; Scheraldi CA; Li X; Ide H; Goldberg IJ; Le NA J Lipid Res; 1993 Oct; 34(10):1793-803. PubMed ID: 8245727 [TBL] [Abstract][Full Text] [Related]
5. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634 [TBL] [Abstract][Full Text] [Related]
6. Plasma lipoprotein lipase, hepatic lipase activities, VLDL, LDL compositions at different times of hemodialysis. Mekki K; Prost J; Bouchenak M; Remaoun M; Belleville J Atherosclerosis; 2003 Aug; 169(2):269-77. PubMed ID: 12921978 [TBL] [Abstract][Full Text] [Related]
7. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Nishizawa Y; Shoji T; Emoto M; Kawasaki K; Konishi T; Tabata T; Inoue T; Morii H Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882 [TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)2 and the larger HDL3 from very low-density lipoprotein (VLDL). Yamazaki A; Ohkawa R; Yamagata Y; Horiuchi Y; Lai SJ; Kameda T; Ichimura N; Tohda S; Tozuka M Biol Chem; 2021 May; 402(4):439-449. PubMed ID: 33934596 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Lee DM; Knight-Gibson C; Samuelsson O; Attman PO; Wang CS; Alaupovic P Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103 [TBL] [Abstract][Full Text] [Related]
10. Short-term effects of renal transplantation on plasma lipids and lipoprotein lipase in children with congenital nephrosis. Antikainen M; Holmberg C; Taskinen MR Clin Nephrol; 1994 May; 41(5):284-9. PubMed ID: 8050208 [TBL] [Abstract][Full Text] [Related]
11. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Attman PO; Alaupovic P; Tavella M; Knight-Gibson C Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654 [TBL] [Abstract][Full Text] [Related]
12. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. Wang CS; McConathy WJ; Kloer HU; Alaupovic P J Clin Invest; 1985 Feb; 75(2):384-90. PubMed ID: 3973011 [TBL] [Abstract][Full Text] [Related]
13. Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation. Silbernagel G; Chen YQ; Rief M; Kleber ME; Hoffmann MM; Stojakovic T; Stang A; Sarzynski MA; Bouchard C; März W; Qian YW; Scharnagl H; Konrad RJ Eur Heart J; 2023 Jul; 44(25):2335-2345. PubMed ID: 37155355 [TBL] [Abstract][Full Text] [Related]
14. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. Tory R; Sachs-Barrable K; Goshko CB; Hill JS; Wasan KM Transplantation; 2009 Jul; 88(1):62-8. PubMed ID: 19584682 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786 [TBL] [Abstract][Full Text] [Related]
16. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice. Jong MC; Havekes LM Int J Tissue React; 2000; 22(2-3):59-66. PubMed ID: 10937355 [TBL] [Abstract][Full Text] [Related]
17. Metabolism of plasma cholesterol and lipoprotein parameters are related to a higher degree of insulin sensitivity in high HDL-C healthy normal weight subjects. Leança CC; Nunes VS; Panzoldo NB; Zago VS; Parra ES; Cazita PM; Jauhiainen M; Passarelli M; Nakandakare ER; de Faria EC; Quintão EC Cardiovasc Diabetol; 2013 Nov; 12():173. PubMed ID: 24267726 [TBL] [Abstract][Full Text] [Related]
18. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484 [TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase. Conde-Knape K; Bensadoun A; Sobel JH; Cohn JS; Shachter NS J Lipid Res; 2002 Dec; 43(12):2136-45. PubMed ID: 12454276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]